Latest Tapimmune Inc (TPIVD) Headlines TapImmune
Post# of 24
Posted On: 03/11/2014 8:42:33 PM
Latest Tapimmune Inc (TPIVD) Headlines
TapImmune Inc. To Present at 2014 Annual Roth Capital Growth Stock Conference
ACCESSWIRE - Wed Mar 05, 7:31AM CST
Seattle, WA / ACCESSWIRE / March 5, 2014 / TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, will be presenting at the Annual Roth Capital Growth Stock Conference on March 12 2014.
TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ Breast Cancer
Business Wire - Mon Mar 03, 7:00AM CST
TapImmune Inc. (OTCQB:TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes. The Phase I trial is being carried at the Mayo Clinic, Rochester, MN.
TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress
Business Wire - Thu Feb 27, 8:38AM CST
TapImmune Inc. (OTCQB:TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.
TapImmune Inc. To Present at 2014 Annual Roth Capital Growth Stock Conference
ACCESSWIRE - Wed Mar 05, 7:31AM CST
Seattle, WA / ACCESSWIRE / March 5, 2014 / TapImmune Inc. (OTCQB: TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, will be presenting at the Annual Roth Capital Growth Stock Conference on March 12 2014.
TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ Breast Cancer
Business Wire - Mon Mar 03, 7:00AM CST
TapImmune Inc. (OTCQB:TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes. The Phase I trial is being carried at the Mayo Clinic, Rochester, MN.
TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress
Business Wire - Thu Feb 27, 8:38AM CST
TapImmune Inc. (OTCQB:TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.
(0)
(0)Marker Therapeutics, Inc. (MRKR) Stock Research Links
Scroll down for more posts ▼